Bayer to tap into ConcertAI’s longitudinal clinical molecular database for precision oncology insights

Bayer has entered a multi-year agreement with ConcertAI to accelerate precision oncology research by leveraging ConcertAI’s Translational360™ platform, real-world clinical and molecular data, and advanced AI solutions.

ConcertAI and Bayer have announced a multi-year strategic agreement to advance clinical development in precision oncology. Under the collaboration, Bayer will leverage ConcertAI’s Translational360™ platform and its AI and machine learning (ML) solutions to enhance research and development capabilities.

ConcertAI, a provider of predictive and generative AI SaaS and real-world data (RWD) solutions for healthcare and life sciences, partners with more than 46 biomedical innovators, 2000 healthcare providers, and leading medical societies to support research and clinical care initiatives.

At the center of the partnership is Translational360™, an integrated, research-grade longitudinal clinical molecular database. The platform combines clinical, genomic, transcriptomic, and whole-slide imaging (WSI) data, and is powered by Guardant Health’s liquid biopsy genomic data. It also incorporates de-identified cancer patient records from CancerLinQ®, comprising data from more than 9 million patients across the US.

“This partnership furthers causal biological inferences, where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster," said Jeff Elton, PhD, CEO of ConcertAI.

Translational360™ enables deeper phenotypical and genomic insights, helping researchers better understand disease mechanisms, variability in patient responses, and potential therapeutic targets. By integrating comprehensive molecular data with AI-driven insights, the platform aims to address the challenges of ambiguous results often seen in early-phase clinical trials, supporting the prioritization of programs with the highest potential for success and informing clinical trial design.

Commenting on the collaboration, Sai Jasti, Head of Data Science and AI for Pharma R&D at Bayer, said,

“As cancer rates continue to rise, we're committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster. By combining ConcertAI’s powerful data solutions with Bayer’s scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.”

A key feature of the partnership is the use of both tissue and liquid biopsy molecular data, enabling researchers to explore treatment response patterns, resistance mechanisms, and potential clinical outcomes through AI modeling.

Helmy Eltoukhy, Chairman and co-CEO of Guardant Health, emphasized the importance of RWD, stating,

“The real-world data can provide access to unprecedented insights into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help users navigate critical decision points as they develop novel targeted therapies.”

Claudio D’Ambrosio, PhD, Chief Revenue Officer of ConcertAI, added,

“Our entire R&D process has been historically built on studying controlled cell lines and animal models that don’t reflect the interspecies differences, the physiology, and the different biological barriers we have in humans. We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and ‘reverse translate.’ Unlike only a few years ago, we now have powerful human data.”